TransEnterix, Inc. (TRXC) Position Increased by Wells Fargo & Company MN

Wells Fargo & Company MN boosted its holdings in shares of TransEnterix, Inc. (NYSEAMERICAN:TRXC) by 40.1% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 168,146 shares of the medical instruments supplier’s stock after buying an additional 48,102 shares during the period. Wells Fargo & Company MN’s holdings in TransEnterix were worth $975,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the stock. US Bancorp DE raised its stake in TransEnterix by 170.6% during the 3rd quarter. US Bancorp DE now owns 27,060 shares of the medical instruments supplier’s stock valued at $157,000 after purchasing an additional 17,060 shares during the period. California Public Employees Retirement System raised its stake in TransEnterix by 12.4% during the 2nd quarter. California Public Employees Retirement System now owns 181,463 shares of the medical instruments supplier’s stock valued at $791,000 after purchasing an additional 20,063 shares during the period. Steward Partners Investment Advisory LLC bought a new stake in TransEnterix during the 3rd quarter valued at approximately $119,000. Tradewinds Capital Management LLC raised its stake in TransEnterix by 11,260.0% during the 3rd quarter. Tradewinds Capital Management LLC now owns 22,720 shares of the medical instruments supplier’s stock valued at $132,000 after purchasing an additional 22,520 shares during the period. Finally, Legal & General Group Plc bought a new stake in TransEnterix during the 2nd quarter valued at approximately $101,000.

TRXC has been the topic of a number of research reports. LADENBURG THALM/SH SH raised TransEnterix from a “neutral” rating to a “buy” rating and set a $5.00 price objective on the stock in a research note on Friday, November 9th. BTIG Research reaffirmed a “hold” rating on shares of TransEnterix in a research note on Tuesday, September 25th. Finally, Zacks Investment Research raised TransEnterix from a “hold” rating to a “buy” rating and set a $2.50 price objective on the stock in a research note on Saturday, January 5th.

NYSEAMERICAN:TRXC opened at $2.69 on Monday. TransEnterix, Inc. has a 1 year low of $1.27 and a 1 year high of $6.98.

TransEnterix (NYSEAMERICAN:TRXC) last released its quarterly earnings data on Thursday, November 8th. The medical instruments supplier reported ($0.06) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.07) by $0.01. The firm had revenue of $5.40 million during the quarter, compared to the consensus estimate of $5.40 million. The firm’s revenue for the quarter was up 2850.8% on a year-over-year basis.

COPYRIGHT VIOLATION WARNING: “TransEnterix, Inc. (TRXC) Position Increased by Wells Fargo & Company MN” was originally published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.com-unik.info/2019/01/14/transenterix-inc-trxc-position-increased-by-wells-fargo-company-mn.html.

TransEnterix Company Profile

TransEnterix, Inc, a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe.

Featured Article: What is a Market Correction?

Want to see what other hedge funds are holding TRXC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransEnterix, Inc. (NYSEAMERICAN:TRXC).

Institutional Ownership by Quarter for TransEnterix (NYSEAMERICAN:TRXC)

Receive News & Ratings for TransEnterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransEnterix and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit